HC Wainwright Reaffirms Buy Rating for Replimune Group (NASDAQ:REPL)

HC Wainwright reaffirmed their buy rating on shares of Replimune Group (NASDAQ:REPL) in a report issued on Monday, Benzinga reports. They currently have a $17.00 target price on the stock.

Several other brokerages have also recently issued reports on REPL. Wedbush restated an outperform rating and issued a $16.00 target price on shares of Replimune Group in a report on Thursday, June 6th. JPMorgan Chase & Co. dropped their target price on Replimune Group from $17.00 to $14.00 and set an overweight rating for the company in a report on Tuesday, August 13th. Roth Capital upgraded Replimune Group to a strong-buy rating in a report on Tuesday, August 27th. Barclays increased their price target on Replimune Group from $13.00 to $17.00 and gave the stock an overweight rating in a report on Friday, June 7th. Finally, Roth Mkm initiated coverage on Replimune Group in a report on Tuesday, August 27th. They set a buy rating and a $17.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and an average price target of $16.20.

Replimune Group Stock Up 0.5 %

Shares of NASDAQ:REPL opened at $11.08 on Monday. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. The business has a fifty day moving average of $10.24 and a two-hundred day moving average of $8.40. The stock has a market cap of $680.48 million, a P/E ratio of -3.42 and a beta of 1.22. Replimune Group has a 52-week low of $4.92 and a 52-week high of $17.93.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.10. On average, research analysts expect that Replimune Group will post -3.08 earnings per share for the current year.

Insider Transactions at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several hedge funds have recently bought and sold shares of the company. Quest Partners LLC lifted its stake in Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after acquiring an additional 3,150 shares in the last quarter. Algert Global LLC lifted its stake in Replimune Group by 5.4% during the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after acquiring an additional 4,340 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after acquiring an additional 4,946 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Replimune Group by 72.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock worth $96,000 after acquiring an additional 4,975 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its position in Replimune Group by 8.1% in the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after purchasing an additional 5,410 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.